AI Maverick Intel (OTC: AIMV) announced the issuance of 76.5 million common shares to HEAL Group Holdings as the initial tranche of consideration under the companies’ Right of First Refusal Agreement dated Feb. 11, 2026, as AIMV advances its proposed acquisition of HEAL Access Canada Inc. The company said the total consideration tied to the transaction has been adjusted from 120 million to 100 million AIMV common shares, with the parties continuing toward a definitive agreement, while also noting plans to pursue an uplisting to the OTCQB Venture Market as part of its broader capital markets strategy.
This issuance represents a significant step in AIMV's strategic plan to acquire HEAL Access Canada Inc., a move that could expand its footprint in the healthcare access and technology space. The revised consideration of 100 million shares, down from the originally proposed 120 million, suggests a renegotiation of terms as due diligence progresses. The agreement grants AIMV a right of first refusal on potential opportunities, positioning the company to leverage HEAL's assets and expertise.
The decision to uplist to the OTCQB Venture Market is a key milestone for AIMV. The OTCQB, operated by OTC Markets Group, requires companies to meet higher financial standards and undergo current reporting, which can enhance visibility and credibility among investors. This uplisting could attract a broader investor base and improve liquidity for AIMV shares.
AI Maverick Intel, Inc. is focused on identifying and developing opportunities at the intersection of artificial intelligence, data platforms, and emerging technology-enabled industries. The Company evaluates strategic acquisitions, partnerships, and scalable platforms designed to drive long-term shareholder value. The proposed acquisition of HEAL Access Canada Inc. aligns with this mission by combining AIMV's AI capabilities with HEAL's healthcare access platform.
For more details on the press release, visit https://ibn.fm/mivWz. The latest news and updates relating to AIMV are available in the company’s newsroom at http://ibn.fm/AIMV.
